scholarly journals Effects of the kappa opioid antagonist nor‐binaltorphimine on cocaine vs. food choice and extended‐access cocaine intake in rhesus monkeys (658.6)

2014 ◽  
Vol 28 (S1) ◽  
Author(s):  
Blake Hutsell ◽  
Matthew Banks ◽  
Steve Negus ◽  
Kenner Rice
Keyword(s):  
Food Choice ◽  
Rhesus Monkeys ◽  
Opioid Antagonist ◽  
Kappa Opioid ◽  
Extended Access

scholarly journals Effects of the kappa opioid receptor antagonist nor-binaltorphimine (nor-BNI) on cocaine versus food choice and extended-access cocaine intake in rhesus monkeys

2015 ◽  
Vol 21 (2) ◽  
pp. 360-373 ◽  
Author(s):  
Blake A. Hutsell ◽  
Kejun Cheng ◽  
Kenner C. Rice ◽  
Sidney Stevens Negus ◽  
Matthew L. Banks
Keyword(s):  
Receptor Antagonist ◽  
Opioid Receptor ◽  
Food Choice ◽  
Rhesus Monkeys ◽  
Kappa Opioid Receptor ◽  
Kappa Opioid ◽  
Opioid Receptor Antagonist ◽  
Extended Access

scholarly journals Effects of Phendimetrazine Treatment on Cocaine vs Food Choice and Extended-Access Cocaine Consumption in Rhesus Monkeys

2013 ◽  
Vol 38 (13) ◽  
pp. 2698-2707 ◽  
Author(s):  
Matthew L Banks ◽  
Bruce E Blough ◽  
Timothy R Fennell ◽  
Rodney W Snyder ◽  
S Stevens Negus
Keyword(s):  
Food Choice ◽  
Rhesus Monkeys ◽  
Extended Access

scholarly journals Lorcaserin maintenance fails to attenuate heroin vs. food choice in rhesus monkeys

2019 ◽  
Author(s):  
E. Andrew Townsend ◽  
S. Stevens Negus ◽  
Justin L. Poklis ◽  
Matthew L. Banks
Keyword(s):  
Food Choice ◽  
Rhesus Monkeys ◽  
Therapeutic Potential ◽  
Day Treatment ◽  
Fixed Ratio ◽  
Dose Effect ◽  
Continuous Treatment ◽  
Opioid Antagonist ◽  
Opioid Use ◽  
Preclinical Research

AbstractBackgroundThe current opioid crisis has reinvigorated preclinical research in the evaluation of non-opioid candidate treatments for opioid use disorder (OUD). Emerging evidence suggests 5-HT2C receptor agonists may attenuate the abuse-related effects of opioids. This study evaluated effectiveness of 7-day treatment with the clinically available 5-HT2C agonist lorcaserin on heroin-vs.-food choice in rhesus monkeys. Lorcaserin effects were compared to effects produced by saline substitution and by 7-day treatment with the opioid antagonist naltrexone.MethodsAdult male (1) and female (6) rhesus monkeys were trained to respond under a concurrent schedule of food delivery (1g pellets, fixed-ratio 100 schedule) and intravenous heroin injections (0-0.032 mg/kg/injection, fixed-ratio 10 schedule) during daily 2h sessions. Heroin choice dose-effect functions were determined daily before and following 7-day saline substitution or 7-day continuous treatment with naltrexone (0.0032-0.032 mg/kg/h, IV) or lorcaserin (0.032-0.32 mg/kg/h, IV).ResultsUnder baseline conditions, increasing heroin doses maintained a dose-dependent increase in heroin choice. Both saline substitution and 7-day naltrexone treatment significantly attenuated heroin choice and produced a reciprocal increase in food choice. Continuous lorcaserin treatment significantly increased heroin choice.ConclusionsIn contrast to saline substitution and naltrexone, lorcaserin treatment was ineffective to reduce heroin-vs.-food choice. These preclinical results do not support the therapeutic potential of lorcaserin as a candidate OUD treatment.

C.6 - CHRONIC PHENDIMETRAZINE TREATMENT REDUCES COCAINE VS. FOOD CHOICE AND EXTENDED-ACCESS COCAINE CONSUMPTION BY RHESUS MONKEYS

2013 ◽  
Vol 24 ◽  
pp. e31-e32
Author(s):  
S.S. Negus ◽  
M.L. Banks ◽  
B.E. Blough ◽  
T.R. Fennell ◽  
R.W. Snyder
Keyword(s):  
Food Choice ◽  
Rhesus Monkeys ◽  
Extended Access

Kappa opioid antagonist effects of the novel kappa antagonist 5?-guanidinonaltrindole (GNTI) in an assay of schedule-controlled behavior in rhesus monkeys

2002 ◽  
Vol 163 (3-4) ◽  
pp. 412-419 ◽  
Author(s):  
Stevens S. Negus ◽  
Nancy K. Mello ◽  
David C. Linsenmayer ◽  
R. Jones ◽  
Philip S. Portoghese
Keyword(s):  
Rhesus Monkeys ◽  
Opioid Antagonist ◽  
The Novel ◽  
Kappa Opioid

kappa-Opioid agonist inhibition of osmotically induced AVP release: preferential action at hypothalamic sites

1996 ◽  
Vol 270 (2) ◽  
pp. E367-E372 ◽  
Author(s):  
N. F. Rossi ◽  
D. P. Brooks
Keyword(s):  
Potent Inhibitor ◽  
Opiate Receptors ◽  
Opioid Antagonist ◽  
Posterior Pituitary ◽  
Opioid Agonist ◽  
Kappa Opioid ◽  
Water Diuresis ◽  
Kappa Agonist ◽  
Opioid Agonists ◽  
Kappa Opioid Agonist

Although several studies indicate that kappa-opioid agonists induce a water diuresis by inhibiting vasopressin (AVP) secretion, the locus of the kappa-receptors (neurohypophysial vs. hypothalamic) responsible for this effect remains unclear. We have ascertained the effect of the selective kappa-agonist BRL-52656 (BRL) on AVP secretion by using compartmentalized rat hypothalamoneurohypophysial explants in culture. When applied to the hypothalamus, nanomolar concentrations of BRL inhibited osmotically stimulated AVP secretion. This response was blocked by the highly selective kappa-opioid antagonist nor-binaltorphimine (BNI). However, osmotically stimulated AVP release was suppressed at the neurohypophysial site only by 100 nM BRL and was not reversed by BNI but only by naloxone. This dose of BRL, administered to the posterior pituitary compartment, did not appear to act by the agonist gaining access to hypothalamic kappa-opiate receptors, because BNI added to the hypothalamus failed to prevent the inhibition of AVP secretion. The data demonstrate that BRL is a potent inhibitor of osmotically stimulated AVP secretion via activation of kappa-opiate receptors within the hypothalamus, but that higher concentrations of the drug may also stimulate non-kappa-neurohypophysial opiate receptors that suppress AVP release.

Sign in / Sign up

Export Citation Format

Share Document